Solange Peters

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


295 publications

In press | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ...
 
Optimizing oral targeted anticancer therapies (OpTAT) study for patients with solid cancer: protocol for a randomized controlled medication adherence program along with a systematic collection and modeling of pharmacokinetic and pharmacodynamic data
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A, Lopez Veronica A., Dolcan A. et al. JMIR Research Protocols.
 
EML4-ALK Variant Impacts ALK Resistance Mutations
Früh M, Peters S JCO.
 
Lung Cancer
Zimmermann Stefan, Peters Solange dans Dicato Mario, Van Cutsem Eric (eds.) Side Effects of Medical Cancer Therapy, Springer.
 
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression.
Tavernari D., Battistello E., Dheilly E., Petruzzella A.S., Mina M., Sordet-Dessimoz J., Peters S., Krueger T., Gfeller D., Riggi N. et al., 2021/06. Cancer discovery, 11 (6) pp. 1490-1507. Peer-reviewed.
 
GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy.
Ancey P.B., Contat C., Boivin G., Sabatino S., Pascual J., Zangger N., Perentes J.Y., Peters S., Abel E.D., Kirsch D.G. et al., 2021/05/01. Cancer research, 81 (9) pp. 2345-2357. Peer-reviewed.
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
 
Suivi téléphonique des patients testés positifs au SARS-CoV-2 au Département d’oncologie du CHUV [Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]
Jankovic J., Da Silva Lopes A.M., Morez A., Darnac C., Demicheli R., Dalla-Vale M., Lauriers N., Garcia Sanchez J., Bouchaab H., Ninane F. et al., 2021/04/07. Revue medicale suisse, 17 (733) pp. 703-707. Peer-reviewed.
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
Mampuya W.A., Bouchaab H., Schaefer N., Kinj R., La Rosa S., Letovanec I., Ozsahin M., Bourhis J., Coukos G., Peters S. et al., 2021/03. Clinical and translational radiation oncology, 27 pp. 85-88. Peer-reviewed.
 
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L., Bouchaab H., Mederos N., Nguyen-Ngoc T., Perreau M., Fenwick C., Vaucher J., Sempoux C., Peters S., Obeid M., 2021/02. Journal of thoracic oncology, 16 (2) pp. 318-326. Peer-reviewed.
 
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
Peters S., Felip E., Dafni U., Tufman A., Guckenberger M., Álvarez R., Nadal E., Becker A., Vees H., Pless M. et al., 2021/02. Journal of thoracic oncology, 16 (2) pp. 278-288. Peer-reviewed.
 
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study.
Forster C., Doucet V., Perentes J.Y., Abdelnour-Berchtold E., Zellweger M., Faouzi M., Bouchaab H., Peters S., Marcucci C., Krueger T. et al., 2021/01. Translational lung cancer research, 10 (1) pp. 93-103. Peer-reviewed.
 
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
Burns T.F., Borghaei H., Ramalingam S.S., Mok T.S., Peters S., 2020/12/10. Journal of clinical oncology, 38 (35) pp. 4208-4218. Peer-reviewed.
 
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S., Curioni-Fontecedro A., Dafni U., Shah R., O'Brien M., Pope A., Fisher P., Spicer J., Roy A., Gilligan D. et al., 2020/12. Annals of oncology, 31 (12) pp. 1734-1745. Peer-reviewed.
 
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V., Paz-Ares L., Besse B., Moreno V., Peters S., Sala M.A., López-Vilariño J.A., Fernández C., Kahatt C., Alfaro V. et al., 2020/12. Lung cancer, 150 pp. 90-96. Peer-reviewed.
Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
Chazan G., Franchini F., Alexander M., Banerjee S., Mileshkin L., Blinman P., Zielinski R., Karikios D., Pavlakis N., Peters S. et al., 2020/12. ESMO open, 5 (6) pp. e001090. Peer-reviewed.
 
Dépistage du cancer pulmonaire en Suisse : Qui ? Comment ? Quand ? [Lung cancer screening in Switzerland : Who ? How ? When ?]
Casutt A., Lovis A., Selby K., Noirez L., Peters S., Beigelman-Aubry C., Krueger T., Soccal P.M., Von Garnier C., 2020/11/18. Revue medicale suisse, 16 (715) pp. 2224-2226. Peer-reviewed.
 
The METeoric rise of MET in lung cancer.
Friedlaender A., Drilon A., Banna G.L., Peters S., Addeo A., 2020/11/15. Cancer, 126 (22) pp. 4826-4837. Peer-reviewed.
COVID-19 and Cancer: Current Challenges and Perspectives.
Bakouny Z., Hawley J.E., Choueiri T.K., Peters S., Rini B.I., Warner J.L., Painter C.A., 2020/11/09. Cancer cell, 38 (5) pp. 629-646. Peer-reviewed.
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
Trama A., Proto C., Whisenant J.G., Torri V., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J., Pancaldi V. et al., 2020/11/09. Cancer cell, 38 (5) pp. 602-604. Peer-reviewed.
 
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
Passaro A., Stenzinger A., Peters S., 2020/11/09. Cancer cell, 38 (5) pp. 624-625. Peer-reviewed.
 
Dépistage du cancer du poumon : que dire à nos patient·e·s en attendant un programme organisé ? [Lung cancer screening: what can we tell our patients while we await a screening program ?]
Selby K., Gubelmann R., Lovis A., Bulliard J.L., Beigelman-Aubry C., Casutt A., Peters S., Krueger T., Von Garnier C., Cornuz J., 2020/11/04. Revue medicale suisse, 16 (713) pp. 2086-2091. Peer-reviewed.
Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.
Mederos N., Friedlaender A., Peters S., Addeo A., 2020/11. ESMO open, 5 (Suppl 4) pp. e000796. Peer-reviewed.
 
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Peters S., Danson S., Hasan B., Dafni U., Reinmuth N., Majem M., Tournoy K.G., Mark M.T., Pless M., Cobo M. et al., 2020/10. Journal of thoracic oncology, 15 (10) pp. 1647-1656. Peer-reviewed.
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
Curigliano G., Banerjee S., Cervantes A., Garassino M.C., Garrido P., Girard N., Haanen J., Jordan K., Lordick F., Machiels J.P. et al., 2020/10. Annals of oncology, 31 (10) pp. 1320-1335. Peer-reviewed.
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Rivera D.R., Peters S., Panagiotou O.A., Shah D.P., Kuderer N.M., Hsu C.Y., Rubinstein S.M., Lee B.J., Choueiri T.K., de Lima Lopes G. et al., 2020/10. Cancer discovery, 10 (10) pp. 1514-1527. Peer-reviewed.
 
Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients.
Vuong D., Bogowicz M., Denzler S., Oliveira C., Foerster R., Amstutz F., Gabryś H.S., Unkelbach J., Hillinger S., Thierstein S. et al., 2020/09. Medical physics, 47 (9) pp. 4045-4053. Peer-reviewed.
 
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl L.M., Hirsch F.R., Hwang D., Botling J., Lopez-Rios F., Bubendorf L., Mino-Kenudson M., Roden A.C., Beasley M.B., Borczuk A. et al., 2020/09. Journal of thoracic oncology, 15 (9) pp. 1409-1424. Peer-reviewed.
 
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
Doms J., Prior J.O., Peters S., Obeid M., 2020/09. Annals of oncology, 31 (9) pp. 1273-1275. Peer-reviewed.
Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Ürün Y., Hussain S.A., Bakouny Z., Castellano D., Kılıçkap S., Morgan G., Mckay R.R., Pels K., Schmidt A., Doroshow D.B. et al., 2020/08. JCO global oncology, 6 pp. 1248-1257. Peer-reviewed.
 
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T., Camidge D.R., Gadgeel S.M., Rosell R., Dziadziuszko R., Kim D.W., Pérol M., Ou S.I., Ahn J.S., Shaw A.T. et al., 2020/08. Annals of oncology, 31 (8) pp. 1056-1064. Peer-reviewed.
 
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin C.M., Awad M.M., Navarro A., Gottfried M., Peters S., Csőszi T., Cheema P.K., Rodriguez-Abreu D., Wollner M., Yang J.C. et al., 2020/07/20. Journal of clinical oncology, 38 (21) pp. 2369-2379. Peer-reviewed.
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C. et al., 2020/07. The Lancet. Oncology, 21 (7) pp. 914-922. Peer-reviewed.
Gender gap: surveying the world for tomorrow.
Garrido P., Tsang J., Peters S., 2020/07. ESMO open, 5 (4). Peer-reviewed.
Testing for COVID-19 in lung cancer patients.
Passaro A., Peters S., Mok TSK, Attili I., Mitsudomi T., de Marinis F., 2020/07. Annals of oncology, 31 (7) pp. 832-834. Peer-reviewed.
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.
Dingemans A.C., Soo R.A., Jazieh A.R., Rice S.J., Kim Y.T., Teo LLS, Warren G.W., Xiao S.Y., Smit E.F., Aerts J.G. et al., 2020/07. Journal of thoracic oncology, 15 (7) pp. 1119-1136. Peer-reviewed.
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R., Shete S., Hsu C.Y., Desai A., de Lima Lopes G. et al., 2020/06/20. Lancet, 395 (10241) pp. 1907-1918. Peer-reviewed.
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
Whisenant J.G., Trama A., Torri V., De Toma A., Viscardi G., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J. et al., 2020/06/08. Cancer cell, 37 (6) pp. 742-745. Peer-reviewed.
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer.
Rubinstein S.M., Steinharter J.A., Warner J., Rini B.I., Peters S., Choueiri T.K., 2020/06/08. Cancer cell, 37 (6) pp. 738-741. Peer-reviewed.
 
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
Haanen J., Ernstoff M.S., Wang Y., Menzies A.M., Puzanov I., Grivas P., Larkin J., Peters S., Thompson J.A., Obeid M., 2020/06. Annals of oncology, 31 (6) pp. 724-744. Peer-reviewed.
Challenges in lung cancer therapy during the COVID-19 pandemic.
Calabrò L., Peters S., Soria J.C., Di Giacomo A.M., Barlesi F., Covre A., Altomonte M., Vegni V., Gridelli C., Reck M. et al., 2020/06. The Lancet. Respiratory medicine, 8 (6) pp. 542-544. Peer-reviewed.
 
Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool.
Gerber A., Da Silva Lopes A., Szüts N., Simon M., Ribordy-Baudat V., Ebneter A., Perrinjaquet C., Gaignard M.E., Nicodet D., Betticher D. et al., 2020/06. Health science reports, 3 (2) pp. e160. Peer-reviewed.
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer.
Passaro A., Addeo A., Von Garnier C., Blackhall F., Planchard D., Felip E., Dziadziuszko R., de Marinis F., Reck M., Bouchaab H. et al., 2020/06. ESMO open, 5 (Suppl 3). Peer-reviewed.
 
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S., Shaw A.T., Besse B., Felip E., Solomon B.J., Soo R.A., Bearz A., Gadgeel S.M., Lin C.C., Kao S. et al., 2020/06. Lung cancer, 144 pp. 10-19. Peer-reviewed.
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen J., Ernstoff M., Wang Y., Menzies A., Puzanov I., Grivas P., Larkin J., Peters S., Thompson J., Obeid M., 2020/06. Journal for immunotherapy of cancer, 8 (1) pp. e000604. Peer-reviewed.
 
Cancer du poumon à petites cellules : prise en charge et nouveautés [Small-cell lung cancer: management and novelties]
Abdelhamid K., Kakourou A., Degrauwe N., Nikolopoulou A., Bouchaab H., Peters S., Nguyen-Ngoc T., Mederos N., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1079-1085. Peer-reviewed.
 
Une période de craintes et de défis : vers un monde meilleur ? []
Dietrich P.Y., Aapro M., Peters S., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1071-1072. Peer-reviewed.
 
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi N.A., Cho B.C., Reinmuth N., Lee K.H., Luft A., Ahn M.J., van den Heuvel M.M., Cobo M., Vicente D., Smolin A. et al., 2020/05/01. JAMA oncology, 6 (5) pp. 661-674. Peer-reviewed.
 
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J., Subbiah V., Besse B., Moreno V., López R., Sala M.A., Peters S., Ponce S., Fernández C., Alfaro V. et al., 2020/05. The Lancet. Oncology, 21 (5) pp. 645-654. Peer-reviewed.
 
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Thunnissen E., Kerr K.M., Dafni U., Bubendorf L., Finn S.P., Soltermann A., Biernat W., Cheney R., Verbeken E., Warth A. et al., 2020/05. Modern pathology, 33 (5) pp. 792-801. Peer-reviewed.
 
Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
Zimmermann S., Dietrich P.Y., Michielin O., Betticher D., Peters S., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 819-822. Peer-reviewed.
 
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement
Budczies Jan, Kazdal Daniel, Allgäuer Michael, Christopoulos Petros, Rempel Eugen, Pfarr Nicole, Weichert Wilko, Fröhling Stefan, Thomas Michael, Peters Solange et al., 2020/04. Lung Cancer, 142 pp. 114-119. Peer-reviewed.
 
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Molina-Vila M.A., Stahel R.A., Dafni U., Jordana-Ariza N., Balada-Bel A., Garzón-Ibáñez M., García-Peláez B., Mayo-de-Las-Casas C., Felip E., Curioni Fontecedro A. et al., 2020/03. Journal of thoracic oncology, 15 (3) pp. 416-425. Peer-reviewed.
 
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Schmid S., Früh M., Peters S., 2020/03. The Lancet. Oncology, 21 (3) pp. 320-322. Peer-reviewed.
 
Journée du cancer : mobiliser autour de la prévention []
Peters S., Dietrich P.Y., 2020/02/19. Revue medicale suisse, 16 (682) pp. 382-383. Peer-reviewed.
 
Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navi© Programme.
Bana M., Ribi K., Kropf-Staub S., Näf E., Schramm M.S., Zürcher-Florin S., Peters S., Eicher M., 2020/02. European journal of oncology nursing, 44 p. 101714. Peer-reviewed.
 
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Park K., Vansteenkiste J., Lee K.H., Pentheroudakis G., Zhou C., Prabhash K., Seto T., Voon P.J., Tan DSW, Yang JCH et al., 2020/02. Annals of oncology, 31 (2) pp. 191-201. Peer-reviewed.
 
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary.
Malebranche M., Sarivalasis A., Peters S., Mathevet P., Cornuz J., Bodenmann P., 2020. Journal of primary care & community health, 11 p. 2150132720957455. Peer-reviewed.
 
Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.
De Ruysscher D., Faivre-Finn C., Nackaerts K., Jordan K., Arends J., Douillard J.Y., Ricardi U., Peters S., 2020/01. Annals of oncology, 31 (1) pp. 41-49. Peer-reviewed.
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study.
Pozzessere C., Bouchaab H., Jumeau R., Letovanec I., Daccord C., Bourhis J., Prior J.O., Peters S., Lazor R., Beigelman-Aubry C., 2020/01. ERJ open research, 6 (1). Peer-reviewed.
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V., Dunet V., Hottinger A.F., Berthod G., Schiappacasse L., Peters S., Michielin O., Aedo-Lopez V., 2019/12/02. Journal for immunotherapy of cancer, 7 (1) p. 336. Peer-reviewed.
 
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.
Dingemans A.C., Hendriks LEL, Berghmans T., Levy A., Hasan B., Faivre-Finn C., Giaj-Levra M., Giaj-Levra N., Girard N., Greillier L. et al., 2019/12. Journal of thoracic oncology, 14 (12) pp. 2109-2119. Peer-reviewed.
 
Gender medicine and oncology: report and consensus of an ESMO workshop.
Wagner A.D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G.P., Ducreux M. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1914-1924. Peer-reviewed.
 
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M., Pavlakis N., Levchenko E., Platania M., Oliveira J., Novello S., Chiari R., Moran T., Mitry E., Nüesch E. et al., 2019/12. Lung cancer, 138 pp. 79-87. Peer-reviewed.
 
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann M.D., Paz-Ares L., Bernabe Caro R., Zurawski B., Kim S.W., Carcereny Costa E., Park K., Alexandru A., Lupinacci L., de la Mora Jimenez E. et al., 2019/11/21. The New England journal of medicine, 381 (21) pp. 2020-2031. Peer-reviewed.
 
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Kazdal D., Endris V., Allgäuer M., Kriegsmann M., Leichsenring J., Volckmar A.L., Harms A., Kirchner M., Kriegsmann K., Neumann O. et al., 2019/11. Journal of thoracic oncology, 14 (11) pp. 1935-1947. Peer-reviewed.
 
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
 
Optimizing panel-based tumor mutational burden (TMB) measurement.
Budczies J., Allgäuer M., Litchfield K., Rempel E., Christopoulos P., Kazdal D., Endris V., Thomas M., Fröhling S., Peters S. et al., 2019/09/01. Annals of oncology, 30 (9) pp. 1496-1506. Peer-reviewed.
 
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis.
Ascierto P.A., Bifulco C., Palmieri G., Peters S., Sidiropoulos N., 2019/09. The Journal of molecular diagnostics, 21 (5) pp. 756-767. Peer-reviewed.
 
<sup>18</sup>F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M., Letovanec I., Chaba K., Renaud S., Rusakiewicz S., Cristina V., Peters S., Krueger T., de Leval L., Kandalaft L.E. et al., 2019/08. European journal of nuclear medicine and molecular imaging, 46 (9) pp. 1859-1868. Peer-reviewed.
 
Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J., Wauters E., Reymen B., Ackermann C.J., Peters S., De Ruysscher D., 2019/08/01. Annals of oncology, 30 (8) pp. 1244-1253. Peer-reviewed.
 
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer.
Früh M., Peters S., 2019/08/01. Annals of oncology, 30 (8) pp. 1190-1192. Peer-reviewed.
 
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U., Tsourti Z., Vervita K., Peters S., 2019/08. Lung cancer, 134 pp. 127-140. Peer-reviewed.
 
The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
Peters S., Clézardin P., Márquez-Rodas I., Niepel D., Gedye C., 2019/08. Clinical & translational oncology, 21 (8) pp. 977-991. Peer-reviewed.
 
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade.
Zimmermann S., Peters S., 2019/07/25. JAMA oncology. Peer-reviewed.
 
Implementation of the Symptom Navi © Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi© Pilot Study).
Bana M., Ribi K., Kropf-Staub S., Zürcher-Florin S., Näf E., Manser T., Bütikofer L., Rintelen F., Peters S., Eicher M., 2019/07/09. BMJ open, 9 (7) pp. e027942. Peer-reviewed.
 
Médecine personnalisée. Bases de la formation interprofessionnelle prégraduée, postgraduée et continue des professionnels de la santé.
Colomer-Lahiguera Sara, 2019/07/08. dans Chapitre 10. La médecine personnalisée en oncologie, Académie Suisse des Sciences Médicales.
 
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S., Felip E., Dafni U., Belka C., Guckenberger M., Irigoyen A., Nadal E., Becker A., Vees H., Pless M. et al., 2019/07. Lung cancer, 133 pp. 83-87. Peer-reviewed.
 
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge D.R., Dziadziuszko R., Peters S., Mok T., Noe J., Nowicka M., Gadgeel S.M., Cheema P., Pavlakis N., de Marinis F. et al., 2019/07. Journal of thoracic oncology, 14 (7) pp. 1233-1243. Peer-reviewed.
 
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Dziadziuszko R., Smit E.F., Dafni U., Wolf J., Wasąg B., Biernat W., Finn S.P., Kammler R., Tsourti Z., Rabaglio M. et al., 2019/06. Journal of thoracic oncology, 14 (6) pp. 1086-1094. Peer-reviewed.
 
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
Peters S., Reck M., Smit E.F., Mok T., Hellmann M.D., 2019/06/01. Annals of oncology, 30 (6) pp. 884-896. Peer-reviewed.
 
De sérieuses préoccupations qui ne cachent pas nos espoirs []
Aapro M., Peters S., Dietrich P.Y., 2019/05/15. Revue medicale suisse, 15 (651) pp. 999-1000. Peer-reviewed.
 
Nouvelles options thérapeutiques du cancer pulmonaire à l’ère de l’immunothérapie [The new management options for lung cancer in the immunotherapy era]
Meganem H., Socianu R.M., Bouchaab H., Mederos N., Nguyen-Ngoc T., Peters S., Dolcan A., 2019/05/15. Revue medicale suisse, 15 (651) pp. 1032-1037. Peer-reviewed.
 
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr K.M., Thunnissen E., Dafni U., Finn S.P., Bubendorf L., Soltermann A., Verbeken E., Biernat W., Warth A., Marchetti A. et al., 2019/05. Lung cancer, 131 pp. 95-103. Peer-reviewed.
 
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.
Martinez P., Peters S., Stammers T., Soria J.C., 2019/05/01. Clinical cancer research, 25 (9) pp. 2691-2698. Peer-reviewed.
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
Curioni-Fontecedro A., Perentes J.Y., Gelpke H., Xyrafas A., Bouchaab H., Mach N., Matzinger O., Stojcheva N., Frueh M., Weder W. et al., 2019/05. British journal of cancer, 120 (10) pp. 968-974. Peer-reviewed.
 
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Lai W.V., Lebas L., Barnes T.A., Milia J., Ni A., Gautschi O., Peters S., Ferrara R., Plodkowski A.J., Kavanagh J. et al., 2019/03. European journal of cancer, 109 pp. 28-35. Peer-reviewed.
 
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
Wu Y.L., Planchard D., Lu S., Sun H., Yamamoto N., Kim D.W., Tan DSW, Yang J.C., Azrif M., Mitsudomi T. et al., 2019/02/01. Annals of oncology, 30 (2) pp. 171-210. Peer-reviewed.
 
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Peters S., Dafni U., Boyer M., De Ruysscher D., Faivre-Finn C., Felip E., Garrido P., Girard N., Guckenberger M., Haanen J. et al., 2019/02/01. Annals of oncology, 30 (2) pp. 161-165. Peer-reviewed.
 
Brain metastases.
Achrol A.S., Rennert R.C., Anders C., Soffietti R., Ahluwalia M.S., Nayak L., Peters S., Arvold N.D., Harsh G.R., Steeg P.S. et al., 2019/01/17. Nature reviews. Disease primers, 5 (1) p. 5. Peer-reviewed.
 
Oncologie [Oncology, what's new in 2018]
Latifyan S., Kakourou A., Ozdemir B., Zaman K., Vernadou A., Berthold D., Abdelhamid K., Bouchaab H., Peters S., Montemurro M. et al., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 78-81. Peer-reviewed.
 
Characterisation of rare haematological immune-related toxicities.
Haanen J.B., Peters S., 2019/01. The Lancet. Haematology, 6 (1) pp. e10-e11. Peer-reviewed.
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
Chan T.A., Yarchoan M., Jaffee E., Swanton C., Quezada S.A., Stenzinger A., Peters S., 2019/01/01. Annals of oncology, 30 (1) pp. 44-56. Peer-reviewed.
 
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
 
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).
Früh M., Betticher D.C., Stupp R., Xyrafas A., Peters S., Ris H.B., Mirimanoff R.O., Ochsenbein A.F., Schmid R., Matzinger O. et al., 2019/01. Journal of thoracic oncology, 14 (1) pp. 115-123. Peer-reviewed.
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F., Sykiotis G.P., Maillard M., Fraga M., Ribi C., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F. et al., 2019/01. The Lancet. Oncology, 20 (1) pp. e54-e64. Peer-reviewed.
 
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Peters S., Stahel R., Bubendorf L., Bonomi P., Villegas A., Kowalski D.M., Baik C.S., Isla D., Carpeno J.C., Garrido P. et al., 2019/01/01. Clinical cancer research, 25 (1) pp. 64-72. Peer-reviewed.
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S., Curioni-Fontecedro A., Nechushtan H., Shih J.Y., Liao W.Y., Gautschi O., Spataro V., Unk M., Chih-Hsin Yang J., Lorence R.M. et al., 2018/12. Journal of thoracic oncology, 13 (12) pp. 1897-1905. Peer-reviewed.
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
Rulle U., Tsourti Z., Casanova R., Deml K.F., Verbeken E., Thunnissen E., Warth A., Sejda A., Cheney R., Speel E.J. et al., 2018/12. Journal of thoracic oncology, 13 (12) pp. 1851-1863. Peer-reviewed.
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Gadgeel S., Peters S., Mok T., Shaw A.T., Kim D.W., Ou S.I., Pérol M., Wrona A., Novello S., Rosell R. et al., 2018/11/01. Annals of oncology, 29 (11) pp. 2214-2222. Peer-reviewed.
 
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J., Soria J.C., Stathis A., Delord J.P., Peters S., Awada A., Aftimos P.G., Bekradda M., Rezai K., Zeng Z. et al., 2018/10/20. Journal of clinical oncology, 36 (30) pp. 3007-3014. Peer-reviewed.
Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015.
Lazzarino T., Martenet S., Mamin R., Du Pasquier R.A., Peters S., Perreau M., Muller O., Hugli O., Cavassini M., Darling KEA, 2018/10/03. BMJ open, 8 (10) pp. e021203. Peer-reviewed.
 
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Planchard D., Popat S., Kerr K., Novello S., Smit E.F., Faivre-Finn C., Mok T.S., Reck M., Van Schil P.E., Hellmann M.D. et al., 2018/10/01. Annals of oncology, 29 (Suppl 4) pp. iv192-iv237. Peer-reviewed.
 
Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018.
Stiefel F., Kiss A., Salmon P., Peters S., Razavi D., Cervantes A., Margulies A., Bourquin C., participants, 2018/10/01. Annals of oncology, 29 (10) pp. 2033-2036. Peer-reviewed.
 
Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration.
Serena A., Dwyer A.A., Peters S., Eicher M., 2018/09. Journal of nursing scholarship, 50 (5) pp. 540-548. Peer-reviewed.
 
Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC.
Zimmermann S., Peters S., 2018/09. Journal of thoracic oncology, 13 (9) pp. 1242-1244. Peer-reviewed.
 
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S., Zimmermann S., 2018/05/28. Current treatment options in oncology, 19 (7) p. 37. Peer-reviewed.
 
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S., Zimmermann S., 2018/05/28. Current treatment options in oncology, 19 (7) p. 37. Peer-reviewed.
 
Immune Checkpoint Inhibitors in the Management of Lung Cancer.
Zimmermann S., Peters S., Owinokoko T., Gadgeel S.M., 2018/05/23. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38 pp. 682-695. Peer-reviewed.
 
De vrais espoirs et de sérieuses préoccupations
Peters S., Dietrich P.Y., Aapro M., 2018/05/16. Revue medicale suisse, 14 (607) pp. 1011-1012. Peer-reviewed.
 
Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
Früh M., Peters S., 2018/05/14. Cancer cell, 33 (5) pp. 791-793. Peer-reviewed.
 
EML4-ALK Variant Affects ALK Resistance Mutations.
Früh M., Peters S., 2018/04/20. Journal of clinical oncology, 36 (12) pp. 1257-1259. Peer-reviewed.
 
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
Letovanec I., Finn S., Zygoura P., Smyth P., Soltermann A., Bubendorf L., Speel E.J., Marchetti A., Nonaka D., Monkhorst K. et al., 2018/03. Journal of thoracic oncology, 13 (3) pp. 413-425. Peer-reviewed.
RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma.
Faget J., Contat C., Zangger N., Peters S., Meylan E., 2018/03. Journal of thoracic oncology, 13 (3) pp. 387-398. Peer-reviewed.
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.
Banerjee S., Dafni U., Allen T., Arnold D., Curigliano G., Garralda E., Garassino M.C., Haanen J., Hofstädter-Thalmann E., Robert C. et al., 2018. ESMO open, 3 (6) pp. e000422. Peer-reviewed.
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S., Kerr K.M., Stahel R., 2018/01. Cancer treatment reviews, 62 pp. 39-49. Peer-reviewed.
 
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Kerr K.M., Dafni U., Schulze K., Thunnissen E., Bubendorf L., Hager H., Finn S., Biernat W., Vliegen L., Losa J.H. et al., 2018/01/01. Annals of oncology, 29 (1) pp. 200-208. Peer-reviewed.
Report on the status of women occupying leadership roles in oncology.
Hofstädter-Thalmann E., Dafni U., Allen T., Arnold D., Banerjee S., Curigliano G., Garralda E., Garassino M.C., Haanen J., Robert C. et al., 2018. ESMO open, 3 (6) pp. e000423. Peer-reviewed.
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
Rizvi N.A., Peters S., 2017/11/16. The New England journal of medicine, 377 (20) pp. 1986-1988. Peer-reviewed.
 
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
Bubendorf L., Dafni U., Schöbel M., Finn S.P., Tischler V., Sejda A., Marchetti A., Thunnissen E., Verbeken E.K., Warth A. et al., 2017/09. Lung cancer, 111 pp. 143-149. Peer-reviewed.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W., Ou S.I., Pérol M., Dziadziuszko R., Rosell R. et al., 2017/08/31. The New England journal of medicine, 377 (9) pp. 829-838. Peer-reviewed.
 
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S., Gettinger S., Johnson M.L., Jänne P.A., Garassino M.C., Christoph D., Toh C.K., Rizvi N.A., Chaft J.E., Carcereny Costa E. et al., 2017/08/20. Journal of clinical oncology, 35 (24) pp. 2781-2789. Peer-reviewed.
 
Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study.
Serena A., Dwyer A., Peters S., Eicher M., 2017/08. European journal of oncology nursing, 29 pp. 106-114. Peer-reviewed.
 
Scientific Advances in Thoracic Oncology 2016.
Soo R.A., Stone ECA, Cummings K.M., Jett J.R., Field J.K., Groen HJM, Mulshine J.L., Yatabe Y., Bubendorf L., Dacic S. et al., 2017/08. Journal of thoracic oncology, 12 (8) pp. 1183-1209. Peer-reviewed.
 
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.
Le Rhun E., Weller M., Brandsma D., Van den Bent M., de Azambuja E., Henriksson R., Boulanger T., Peters S., Watts C., Wick W. et al., 2017/07/01. Annals of oncology, 28 (suppl_4) pp. iv84-iv99. Peer-reviewed.
 
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Postmus P.E., Kerr K.M., Oudkerk M., Senan S., Waller D.A., Vansteenkiste J., Escriu C., Peters S., ESMO Guidelines Committee, 2017/07/01. Annals of oncology, 28 (suppl_4) pp. iv1-iv21. Peer-reviewed.
 
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Haanen JBAG, Carbonnel F., Robert C., Kerr K.M., Peters S., Larkin J., Jordan K., ESMO Guidelines Committee, 2017/07/01. Annals of oncology, 28 (suppl_4) pp. iv119-iv142. Peer-reviewed.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone D.P., Reck M., Paz-Ares L., Creelan B., Horn L., Steins M., Felip E., van den Heuvel M.M., Ciuleanu T.E., Badin F. et al., 2017/06/22. The New England journal of medicine, 376 (25) pp. 2415-2426. Peer-reviewed.
 
L’accès à l’innovation
Aapro M., Dietrich P.Y., Peters S., 2017/05/17. Revue medicale suisse, 13 (563) p. 1027. Peer-reviewed.
 
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O., Rothschild S.I., Li Q., Matter-Walstra K., Zippelius A., Betticher D.C., Früh M., Stahel R.A., Cathomas R., Rauch D. et al., 2017/05. Clinical lung cancer, 18 (3) pp. 303-309. Peer-reviewed.
 
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R., Dafni U., Felip E., Curioni-Fontecedro A., Gautschi O., Peters S., Massutí B., Palmero R., Aix S.P., Carcereny E. et al., 2017/05. The Lancet. Respiratory medicine, 5 (5) pp. 435-444. Peer-reviewed.
 
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
Peters S., Stahel R.A., Dafni U., Ponce Aix S., Massutí B., Gautschi O., Coate L., López Martín A., van Heemst R., Berghmans T. et al., 2017/04. Journal of thoracic oncology, 12 (4) pp. 752-762. Peer-reviewed.
 
Current Trends in Thoracic Radio-oncology
Matzinger O, Peters S, 2017/02/01. Schweizer Krebsbulletin, Nr 2/2017.
 
ETOP and its role in lung cancer research in Europe
Roschitzki-Voser H, Maibach R, Stahel R, Peters S, 2017/02/01. Schweizer Krebsbulletin, Nr 2/2017.
 
Feasibility of advanced practice nurse in lung cancer consultations during early treatment: a phase II study
Serena A., Dwyer A., Peters S., Eicher M., 2017/02. European Journal of Cancer, 72 pp. S160.
 
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C., Dingemans A.C., Gray J.E., Nakagawa K., Nicolson M., Peters S., Reck M., Wu Y.L., Brustugun O.T., Crinò L. et al., 2017/02. Journal of thoracic oncology, 12 (2) pp. 194-207. Peer-reviewed.
 
Un regard critique sur l’innovation
Peters S, 2017/02/01. Schwerpunktthema "Lungenkrebs" Schweizer Krebsbulletin, Nr 2/2017..
 
Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project
Finn S., Letovanec I., Zygoura P., Smyth P., Soltermann A., Bubendorf L., Speel EJ, Marchetti A., Nonaka D., Monkhorst K. et al., 2017/01/31. pp. S501-S502 dans Journal of Thoracic Oncology.
 
ESMO Handbook of Immuno-Oncology
Peters Solange, Zimmermann Stefan, 2017/01/01., ESMO.
 
Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer
Nguyen-Ngoc Tu, Reck Martin, Tan Daniel SW, Peters Solange, 2017. European Oncology & Haematology, 13 (01) p. 35.
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
Manegold Christian, Adjei Alex, Bussolino Federico, Cappuzzo Federico, Crino Lucio, Dziadziuszko Rafal, Ettinger David, Fennell Dean, Kerr Keith, Le Chevalier Thierry et al., 2017/01. ESMO Open, 1 (6) pp. e000118. Peer-reviewed.
Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study.
De Rossi N., Dattner N., Cavassini M., Peters S., Hugli O., Darling KEA, 2017. PloS one, 12 (7) pp. e0180389. Peer-reviewed.
 
Side Effects of Medical Cancer Therapy, 2nd Edition
Dicato Mario (eds.)Peters Solange, 2017/01/01., Springer Verlag .
 
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology.
Peters Solange (eds.), 2016/11., 11 11S.
 
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy
Owonikoko T., Ready N., Postmus P., Reck M., Peters S., Pieters A., Selvaggi G., Fairchild J., Govindan R., 2016/11. pp. S306-S307 dans Journal of Thoracic Oncology. Peer-reviewed, Elsevier BV.
 
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy: Topic: Medical Oncology.
Owonikoko T., Ready N., Postmus P., Reck M., Peters S., Pieters A., Selvaggi G., Fairchild J., Govindan R., 2016/11. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 11 (11S) pp. S306-S307. Peer-reviewed.
 
Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.
Merz L., Zimmermann S., Peters S., Cavassini M., Darling K.E., 2016/10. The oncologist, 21 (10) pp. 1176-1182. Peer-reviewed.
 
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
Früh M., Ris H.B., Xyrafas A., Peters S., Mirimanoff R.O., Gautschi O., Pless M., Stupp R., 2016/10. Annals of oncology, 27 (10) pp. 1971-1973. Peer-reviewed.
 
Scientific Advances in Lung Cancer 2015.
Tsao A.S., Scagliotti G.V., Bunn P.A., Carbone D.P., Warren G.W., Bai C., de Koning H.J., Yousaf-Khan A.U., McWilliams A., Tsao M.S. et al., 2016/05. Journal of thoracic oncology, 11 (5) pp. 613-638. Peer-reviewed.
 
The French initiative paves the way: routine molecular profiling of advanced non-small-cell lung cancer fights inequalities in access to molecular targeted therapy and improves patient outcome
Peters Solange, Zimmermann Stefan, 2016/04. Translational Cancer Research, 5 (2) pp. 124-126.
 
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J., Barlesi F., Filleron T., Besse B., Monnet I., Beau-Faller M., Peters S., Dansin E., Früh M., Pless M. et al., 2016/02. Annals of oncology : official journal of the European Society for Medical Oncology, 27 (2) pp. 281-286. Peer-reviewed.
 
191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.
Peters S., Antonia S., Goldberg S.B., Heymach J.V., Kim E.S., Nakagawa K., Papadimitrakopoulou V., Mukhopadhyay P., McIntosh S., Rizvi N.A., 2016..
 
Apnea-like suppression of respiratory motion: First evaluation in radiotherapy.
Péguret N., Ozsahin M., Zeverino M., Belmondo B., Durham A.D., Lovis A., Simons J., Long O., Duclos F., Prior J. et al., 2016. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology, 118 (2) pp. 220-226. Peer-reviewed.
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.
Tabernero J., Vyas M., Giuliani R., Arnold D., Cardoso F., Casali P.G., Cervantes A., Eggermont A.M., Eniu A., Jassem J. et al., 2016. ESMO open, 1 (6) pp. e000142. Peer-reviewed.
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
Morgan G., Lambertini M., Kourie H.R., Amaral T., Argiles G., Banerjee S., Cardone C., Corral J., De Mattos-Arruda L., Öztürk A. et al., 2016. ESMO open, 1 (6) pp. e000107. Peer-reviewed.
 
Emerging Options After Progression During Crizotinib Therapy.
Peters S., 2016. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 34 (7) pp. 643-645. Peer-reviewed.
 
Lung Cancer
Zimmermann Stefan, Peters Solange, Dziadziuszko Rafal, Baumann Michael, Mitsudomi Tetsuya, Kerr Keith K., 2016/01. dans Kerr David J., Haller Daniel G., van der Velde Cornelis J. H., Baumann Michael, Nagahiro Saijo (eds.) Oxford Textbook of Oncology, Oxford University Press.
 
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Novello S., Barlesi F., Califano R., Cufer T., Ekman S., Levra M.G., Kerr K., Popat S., Reck M., Senan S. et al., 2016. Annals of Oncology : Official Journal of the European Society For Medical Oncology, 27 (suppl 5) pp. v1-v27. Peer-reviewed.
 
Seeking New Approaches to Patients With Small Cell Lung Cancer
Pietanza Marie Catherine, Zimmermann Stefan, Peters Solange, Curran Walter J., 2016. pp. e477-e482 dans American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology (ASCO).
 
Seeking New Approaches to Patients With Small Cell Lung Cancer.
Pietanza M.C., Zimmerman S., Peters S., Curran W.J., 2016. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 35 pp. e477-82. Peer-reviewed.
 
Survival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy.
Abdelnour-Berchtold E., Perentes J.Y., Ris H.B., Beigelman C., Lovis A., Peters S., Krueger T., Gonzalez M., 2016. World Journal of Surgery, 40 (2) pp. 373-379. Peer-reviewed.
 
The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.
Peters S., Bexelius C., Munk V., Leighl N., 2016. Cancer Treatment Reviews, 45 pp. 139-162. Peer-reviewed.
 
Ist die Verordnung einer Therapie von 150 000 CHF vertretbar? [Is prescription of a therapy costing 150,000 CHF reasonable?]
Peters S., von Moos R., Thurlimann B., 2015/10/21. Revue medicale suisse, 11 (491) pp. 1967-1972. Peer-reviewed.
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Baas P., Fennell D., Kerr K.M., Van Schil P.E., Haas R.L., Peters S., ESMO Guidelines Committee, 2015/09. Annals of oncology : official journal of the European Society for Medical Oncology, 26 Suppl 5 pp. v31-9. Peer-reviewed.
 
The ESMO guideline strategy: an identity statement and reflections on improvement.
Pentheroudakis G., Cardoso F., Arnold D., Sessa C., Peters S., Horwich A., Pavlidis N., Stahel R., Cervantes A., ESMO Guidelines Committee, 2015/09. Annals of oncology, 26 Suppl 5 pp. v1-7. Peer-reviewed.
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Girard N., Ruffini E., Marx A., Faivre-Finn C., Peters S., ESMO Guidelines Committee, 2015/09. Annals of oncology, 26 (Suppl 5) pp. v40-55. Peer-reviewed.
 
Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no 'sweetheart' solution.
Tabernero J., ESMO Executive Board, 2015/08. Annals of oncology, 26 (8) pp. 1529-1531. Peer-reviewed.
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
Eberhardt W.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S. et al., 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 26 (8) pp. 1573-1588. Peer-reviewed.
 
Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Rolfo O, Gil-Bazo I, Peters S, 2015. European Oncology & Haematology, 2015;11(2):94–9. pp. 94-99.
 
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Gautschi O., Mach N., Rothschild S.I., Li Q., Stahel R.A., Zippelius A., Cathomas R., Früh M., Betticher D.C., Peters S. et al., 2015. Clinical Lung Cancer, 16 (5) pp. 358-365. Peer-reviewed.
 
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T., Bouchaab H., Adjei A.A., Peters S., 2015. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer, 10 (10) pp. 1396-1403. Peer-reviewed.
 
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M., Stupp R., Ris H.B., Stahel R.A., Weder W., Thierstein S., Gerard M.A., Xyrafas A., Früh M., Cathomas R. et al., 2015. Lancet, 386 (9998) pp. 1049-1056. Peer-reviewed.
 
Lung cancer: How much platinum-based chemotherapy is enough in NSCLC?
Peters S., Adjei A.A., 2015. Nature Reviews. Clinical Oncology, 12 (1) pp. 8-10.
 
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel R.A., Riesterer O., Xyrafas A., Opitz I., Beyeler M., Ochsenbein A., Früh M., Cathomas R., Nackaerts K., Peters S. et al., 2015. Lancet. Oncology, 16 (16) pp. 1651-1658. Peer-reviewed.
 
Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development.
Stahel R., Bogaerts J., Ciardiello F., de Ruysscher D., Dubsky P., Ducreux M., Finn S., Laurent-Puig P., Peters S., Piccart M. et al., 2015. Cancer Treatment Reviews, 41 (2) pp. 129-135. Peer-reviewed.
 
P3.04-009: Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project
Letovanec I., Peters S., Tsourti Z., Finn SP, Soltermann A., Bubendorf L., Speel EJM, Marchetti A., Nonaka D., Hager H. et al., 2015. pp. S693-S694 dans 16th World Conference on Lung Cancer, Journal of Thoracic Oncology. Peer-reviewed.
Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study.
Favre-Bulle T., Baudat D., Darling K., Mamin R., Peters S., Cavassini M., Hugli O., 2015. Swiss Medical Weekly, 145 pp. w14206. Peer-reviewed.
 
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer.
Zimmermann S., Peters S., 2015. Cancer Metastasis Reviews, 34 (2) pp. 173-182. Peer-reviewed.
Searching for targets for the systemic therapy of mesothelioma.
Stahel R.A., Weder W., Felley-Bosco E., Petrausch U., Curioni-Fontecedro A., Schmitt-Opitz I., Peters S., 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 26 (8) pp. 1649-1660. Peer-reviewed.
 
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O., Milia J., Cabarrou B., Bluthgen M.V., Besse B., Smit E.F., Wolf J., Peters S., Früh M., Koeberle D. et al., 2015. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer, 10 (10) pp. 1451-1457. Peer-reviewed.
 
The role of advanced nursing in lung cancer: A framework based development.
Serena A., Castellani P., Fucina N., Griesser A.C., Jeanmonod J., Peters S., Eicher M., 2015. European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society, 19 (6) pp. 740-746. Peer-reviewed.
 
Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.
Wang X., Gronchi F., Bensimon M., Mercier T., Decosterd L.A., Wagnières G., Debefve E., Ris H.B., Letovanec I., Peters S. et al., 2015. Lasers In Surgery and Medicine, 47 (10) pp. 807-816. Peer-reviewed.
 
Personalized Treatment of Advanced Non-small Cell Lung Cancer: EGFR Tyrosine Kinase Inhibitors as a Standard of Care
Stravodimou Athina, Peters Solange, 2014/12/05. The Journal of OncoPathology, 1 (4) pp. 63-71.
 
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.
Peters S., Weder W., Dafni U., Kerr K.M., Bubendorf L., Meldgaard P., O'Byrne K.J., Wrona A., Vansteenkiste J., Felip E. et al., 2014/11. Journal of thoracic oncology, 9 (11) pp. 1675-1684. Peer-reviewed.
 
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S., Zimmermann Stefan, Adjei A.A., 2014/09. Cancer treatment reviews, 40 (8) pp. 917-926. Peer-reviewed.
Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network, 2014/07/31. Nature, 511 (7511) pp. 543-550. Peer-reviewed.
 
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Zimmermann Stefan, Dziadziuszko R., Peters S., 2014/07. Cancer treatment reviews, 40 (6) pp. 716-722. Peer-reviewed.
 
La radiothérapie postopératoire a-t-etlle une place dans le cancer pulmonaire ? [Postoperative radiation therapy in lung carcinom]
Bouchaab H., Peters S., Ozsahin M., Peguret N., Gonzales M., Lovis A., 2014/05/21. Revue medicale suisse, 10 (431) pp. 1110-1113. Peer-reviewed.
 
Targeted therapy in NSCLC driven by HER2 insertions.
Peters S., Zimmermann Stefan, 2014/04. Translational lung cancer research, 3 (2) pp. 84-88. Peer-reviewed.
 
Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.
Voide C., Zimmermann Stefan, Adjei A.A., Betticher D.C., Meuli R., Prod'hom G., Giulieri S., Peters S., 2014/03. Journal of thoracic oncology, 9 (3) pp. e24-6. Peer-reviewed.
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Besse B., Adjei A., Baas P., Meldgaard P., Nicolson M., Paz-Ares L., Reck M., Smit E.F., Syrigos K., Stahel R. et al., 2014. Annals of Oncology, 25 (8) pp. 1475-1484.
 
ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C., Peters S., Sgambato A., Casaluce F., Adjei A.A., Ciardiello F., 2014. Cancer Treatment Reviews, 40 (2) pp. 300-306.
 
Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.
Voide C., Zimmermann S., Adjei A.A., Betticher D.C., Meuli R., Prod'hom G., Giulieri S., Peters S., 2014. Journal of Thoracic Oncology, 9 (3) pp. e24-e26.
 
Defining the role of targeted therapy in early NSCLC.
Peters S., 2014. dans ESMO 2014.
 
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
Ciardiello F., Arnold D., Casali P.G., Cervantes A., Douillard J.Y., Eggermont A., Eniu A., McGregor K., Peters S., Piccart M. et al., 2014. Annals of Oncology, 25 (9) pp. 1673-1678.
 
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S., Bouchaab H., Zimmerman S., Bucher M., Gaide O., Letovanec I., Homicsko K., Michielin O., 2014. Melanoma Research, 24 (5) pp. 496-500.
Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up : 2nd ESMO Consensus Conference on Lung Cancer.
Vansteenkiste J., Crinò L., Dooms C., Douillard J.Y., Faivre-Finn C., Lim E., Rocco G., Senan S., Van Schil P., Veronesi G. et al., 2014. Annals of Oncology, 25 (8) pp. 1462-1474. Peer-reviewed.
 
ESMO advanced lung cancer Guidelines
Peters S., 2014. dans 39th ESMO Congress (ESMO 2014).
 
Final results of the SAKK 16/00 trial: a randomized phase III trial comparing neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small cell lung cancer (NSCLC).
Pless M, Roger R, Ris HB, Stahel R, Weder W, Thierstein S, Xyrafas A, Früh M, Cathomas R, Zippelius A et al., 2014. pp. iv417 dans 39th ESMO Congress (ESMO 2014), Annals of Oncology.
 
Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer
Peters S, Voss A, Russell K, Millis SZ, Brambilla E, 2014. p. 8087 dans 50th Annual Meeting of the American Society of Clinical-Oncology, Journal 0f Clinical Oncology.
 
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Zimmermann S., Dziadziuszko R., Peters S., 2014. Cancer Treatment Reviews, 40 (6) pp. 716-722. Peer-reviewed.
 
Investigating Barriers in HIV-Testing Oncology Patients. The IBITOP study: Phase I
Darling K, Merz L, Zimmermann S, Peters S, Cavassini M, 2014. dans Joint Annual Meeting SSI SSHH SFTRM, 2014.
 
Investigating Barriers in HIV-Testing Oncology Patients. The IBITOP study: Phase I.
Darling KEA, Merz L, Zimmermann S, Peters S, Cavassini M*, 2014. dans Joint annual meeting.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University